Exploring Regeneron Pharmaceuticals, Inc. (REGN) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Regeneron Pharmaceuticals, Inc. (REGN), and what drives their investment decisions? As of April 2025, 2455 institutional owners and shareholders have filed forms with the Securities Exchange Commission (SEC), holding a total of 114,807,900 shares. Dive in to explore the key institutional investors, their stakes, and the factors influencing their positions in this leading biotechnology company, and uncover the dynamics of institutional ownership and its potential impact on the company's future.

Regeneron Pharmaceuticals, Inc. (REGN) Who Invests in [Company Name] and Why?

Understanding the investor profile of Regeneron Pharmaceuticals, Inc. (REGN) provides valuable insights into the market's perception of the company's potential and stability. Analyzing who invests in Regeneron and their motivations can shed light on the overall investment landscape and future prospects. Here’s a detailed exploration of Regeneron’s investor base.

Key Investor Types

Regeneron's shareholder base is composed of a mix of different investor types, each with their own investment strategies and objectives:

• Institutional Investors: These entities, such as mutual funds, pension funds, and insurance companies, represent a significant portion of Regeneron's shareholders. They typically invest large sums of money and often have a long-term investment horizon.
• Retail Investors: Individual investors who buy and sell shares for their own accounts. Their investment decisions can be influenced by a variety of factors, including company performance, market trends, and personal financial goals.
• Hedge Funds: These are investment partnerships that use pooled funds and employ various strategies to earn active return, or alpha, for their investors. They may take both long and short positions and can be more active traders.
• Insider Holdings: Shares held by the company’s executives and board members. These holdings can provide insights into the management’s confidence in the company’s future performance.

Institutional investors form the majority of Regeneron's shareholders. According to recent data, the top institutional holders include well-known investment firms. For example, as of December 31, 2023:

• Vanguard Group held approximately 8.5% of the shares.
• BlackRock Fund Advisors held around 7.2%.
• State Street Corporation held roughly 4.1%.

These significant holdings by large institutional investors suggest a strong confidence in Regeneron's long-term prospects.

Investment Motivations

Several factors attract investors to Regeneron Pharmaceuticals, Inc.:

• Growth Prospects: Regeneron has a robust pipeline of drug candidates and a history of successful drug development, making it an attractive growth stock. Investors are drawn to the potential for future revenue and earnings growth driven by new drug approvals and market expansion.
• Market Position: Regeneron has established a strong market position with several key products, including EYLEA and Dupixent. Its leadership in the biotechnology sector provides a competitive advantage and attracts investors seeking stable, established companies.
• Innovation and R&D: The company's commitment to research and development (R&D) is a major draw for investors. Regeneron invests heavily in discovering and developing new therapies, which can lead to breakthroughs and significant returns. In 2024, Regeneron's R&D expenses were approximately $3.5 billion, reflecting its dedication to innovation.
• Financial Performance: Strong financial performance, including consistent revenue growth and profitability, makes Regeneron an appealing investment. For example, in fiscal year 2024, Regeneron reported total revenues of $13.11 billion.

Investment Strategies

The investment strategies employed by Regeneron's investors vary depending on their investment goals and risk tolerance:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, focusing on the company's sustained growth and innovation. They view Regeneron as a core holding in their portfolios, expecting it to deliver steady returns over time.
• Growth Investing: Growth investors are attracted to Regeneron's potential for high revenue and earnings growth. They are willing to invest in companies that are reinvesting in their business and expanding their market share.
• Value Investing: Some investors may see Regeneron as undervalued based on its intrinsic value, considering factors like its assets, earnings, and future growth prospects. They believe the market price does not fully reflect the company's potential.
• Active Trading: Hedge funds and other active traders may take short-term positions in Regeneron, aiming to profit from price fluctuations. These strategies can involve frequent buying and selling of shares based on market trends and technical analysis.

A comparative look at Regeneron's key financial metrics against its peers in the biotechnology industry can further illustrate its attractiveness to investors. The following table presents a simplified overview:

This comparison highlights Regeneron's strong revenue growth and significant investment in R&D, making it an appealing choice for investors seeking growth and innovation in the biotech sector.

Understanding the composition, motivations, and strategies of Regeneron's investor base provides critical insights into the company's market valuation and future potential. The mix of institutional, retail, and strategic investors, driven by growth prospects and innovation, underscores Regeneron's position as a key player in the pharmaceutical industry.

To gain further insights into Regeneron's journey, explore Regeneron Pharmaceuticals, Inc. (REGN): History, Ownership, Mission, How It Works & Makes Money.

Regeneron Pharmaceuticals, Inc. (REGN) Institutional Ownership and Major Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

Institutional ownership in Regeneron Pharmaceuticals, Inc. (REGN) reflects the confidence and strategic interest of major financial entities. These large investors can significantly influence the company's stock price and strategic direction through their investment decisions and voting power.

Here are some of the top institutional investors in Regeneron Pharmaceuticals, Inc. (REGN), detailing their holdings:

• Vanguard Group Inc. holds 8,224,643 shares, representing about 7.18% of the company.
• BlackRock Fund Advisors owns 5,837,846 shares, accounting for approximately 5.09% of the company.
• State Street Global Advisors, Inc. possesses 3,673,663 shares, which is roughly 3.20% of the company.
• Geode Capital Management LLC has 1,688,484 shares, making up about 1.47% of the company.
• Capital Research & Management Co. controls 1,537,918 shares, representing around 1.34% of the company.
• Capital World Investors holds 1,489,481 shares, which accounts for approximately 1.30% of the company.
• Northern Trust Corp owns 1,364,178 shares, representing about 1.19% of the company.
• Norges Bank Investment Management possesses 1,183,026 shares, making up roughly 1.03% of the company.
• Bank of New York Mellon Corp. has 994,065 shares, accounting for about 0.87% of the company.
• Price T Rowe Associates Inc. controls 935,437 shares, representing around 0.82% of the company.

Tracking changes in institutional ownership provides insights into market sentiment and potential future stock performance. Increases in institutional holdings can indicate strong confidence in the company's prospects, while decreases might suggest concerns about future performance.

For instance, recent data indicates the following activities among institutional investors:

In the first quarter of 2024, Senator Investment Group LP acquired a new position in Regeneron Pharmaceuticals, purchasing 73,500 shares valued at approximately $70.948 million. Similarly, Morgan Stanley boosted its stake by 24.4% in the fourth quarter of 2023, adding 69,049 shares to their holdings, bringing the total to 352,049 shares worth $301.793 million. However, Bank of New York Mellon Corp reduced its position by 1.6% in the third quarter of 2023, selling 16,530 shares to hold 994,065 shares valued at $763.421 million. Also, BNP Paribas Arbitrage SA lowered its holdings by 48.1% during the same period, selling 9,715 shares to end up with 10,480 shares valued at $8.049 million.

Here is a detailed table summarizing institutional ownership changes:

Institutional investors play a crucial role in Regeneron Pharmaceuticals, Inc. (REGN)'s stock performance and strategic decisions. Their substantial holdings provide significant voting power, influencing corporate governance and strategic initiatives. Moreover, their trading activities can drive stock price volatility, affecting market sentiment and investor confidence.

Interested in the financial health of Regeneron Pharmaceuticals, Inc. (REGN)? Check out: Breaking Down Regeneron Pharmaceuticals, Inc. (REGN) Financial Health: Key Insights for Investors

Regeneron Pharmaceuticals, Inc. (REGN) Key Investors and Their Impact on [Company Name]

Understanding who invests in Regeneron Pharmaceuticals, Inc. (REGN) and why can offer valuable insights into the company's stability, growth potential, and strategic direction. Key investors often wield considerable influence, and their actions can significantly impact stock movements and corporate decisions.

While specific, real-time data on all investors and their recent moves fluctuates constantly, we can look at the general landscape of institutional ownership and significant stakeholders. Institutional investors, such as mutual funds, hedge funds, and pension funds, typically hold a significant percentage of Regeneron's shares. These large entities conduct thorough research before investing, and their decisions can drive market sentiment.

Here are some common types of investors and their potential impact:

• Mutual Funds: These funds pool money from many investors to invest in a diversified portfolio. Large mutual fund ownership in Regeneron suggests confidence in the company's long-term growth prospects.
• Hedge Funds: These funds employ various strategies, including taking large positions in companies they believe are undervalued or have potential for significant change. Activist hedge funds may even seek to influence company management or strategy.
• Pension Funds: These funds invest on behalf of retirees and often have a long-term investment horizon. Their presence can indicate stability in the investor base.
• Individual Investors: High-profile individual investors or company insiders can also hold significant stakes. Their actions are closely watched as they may have unique insights into the company's prospects.

Investor influence can manifest in several ways:

• Voting Rights: Large shareholders have a greater say in corporate governance matters, such as electing board members and approving major transactions.
• Market Sentiment: Significant buying or selling activity by prominent investors can influence other investors and impact the stock price.
• Activism: Activist investors may publicly advocate for changes in company strategy, operations, or capital allocation.

To gain a clearer picture of investor activity, one might typically consult resources that provide updated information on institutional holdings, insider transactions, and potential activist investor involvement. Data regarding the fiscal year 2024 is particularly relevant for assessing current investor sentiment and positioning.

For instance, major institutional holders are likely to include well-known investment firms. Monitoring their quarterly filings (e.g., 13F filings in the United States) can reveal changes in their positions, offering clues about their evolving views on Regeneron's prospects. Keep in mind that the pharmaceutical sector is heavily influenced by clinical trial outcomes, regulatory approvals, and competitive dynamics, so investor decisions often reflect these factors.

Recent moves by key investors, such as increasing or decreasing their stakes, can signal confidence or concern about Regeneron's future performance. Significant investments might indicate anticipation of positive clinical trial results or new product launches, while divestments could reflect concerns about competition, pricing pressures, or regulatory challenges.

Keep abreast of Regeneron Pharmaceuticals, Inc.'s mission, vision, and core values. Read more at: Mission Statement, Vision, & Core Values of Regeneron Pharmaceuticals, Inc. (REGN).

Regeneron Pharmaceuticals, Inc. (REGN) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Regeneron Pharmaceuticals, Inc. (REGN). This involves analyzing the perspectives of major shareholders, recent market behavior, and insights from financial analysts.

Investor Sentiment:

Institutional ownership in Regeneron is significant. As of April 17, 2025, institutions held a substantial portion of the company's shares. Fintel reported that 2,455 institutional owners and shareholders had filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 114,807,900 shares. Major shareholders include:

• Vanguard Group Inc
• BlackRock, Inc.
• Fmr Llc
• Jpmorgan Chase & Co
• State Street Corp
• Capital International Investors

TipRanks data indicates a mix of ownership:

• 57.85% held by Institutional Investors
• 1.94% held by Insiders
• 40.22% held by Public Companies and Individual Investors

However, other data from TipRanks suggests different figures, indicating the complexity in tracking exact ownership percentages:

• 31.03% held by Institutional Investors
• 1.94% held by Insiders
• 26.82% held by Public Companies and Individual Investors

Vanguard is identified as holding the most shares of Regeneron (REGN). The ownership structure impacts decision-making, as large institutional investors can influence management and stock prices through their trading activities. Indian investors sentiment towards Regeneron Pharmaceuticals (REGN) shows that Investment in Regeneron Pharmaceuticals Shares from India has grown by 75.27% over the past 30 days.

Recent Market Reactions:

Regeneron's stock has experienced volatility, influenced by various factors. On March 10, 2025, Regeneron shares jumped 5.3% after positive clinical trial results for Dupixent. However, the stock has also faced downward pressure. Cantor Fitzgerald noted a near 49% reduction in Regeneron's share price over the six months leading up to April 22, 2025, outpacing the biotech sector's decline of 24%. As of April 17, 2025, the share price was $563.16, a 37.44% decline from $900.16 on April 22, 2024.

Factors contributing to market reactions include:

• Concerns about Eylea sales erosion
• Tariff worries
• Overall market sentiment and economic disruptions

Conversely, positive news, such as FDA's Priority Review of Regeneron's application for EYLEA HD, can positively influence the stock.

Analyst Perspectives:

Analysts' opinions on Regeneron vary, reflecting a range of outlooks. Recent analyst ratings and price targets provide insights into these perspectives.

Cantor Fitzgerald resumed coverage on April 22, 2025, with an Overweight rating and a price target of $695. This suggests potential upside, as analyst targets range from $547 to $1,081. Other analysts have adjusted their price targets, with Guggenheim Securities reducing their target to $940 while maintaining a Buy rating, and Bernstein SocGen Group lowering their target to $979, retaining an Outperform rating.

Overall, recent evaluations show varied sentiments. For instance, in the last three months of 2024:

• 23 analysts shared evaluations, expressing mixed perspectives
• The average price target was $1185.96, with a high estimate of $1300.00 and a low estimate of $1015.00

However, more recent data indicates a downward trend in average price targets. As of April 17, 2025, the average target was $831.43, down from a previous average of $912.29.

Key insights from analyst evaluations include:

• Analysts update recommendations based on market conditions and company performance.
• Ratings range from 'Outperform' to 'Underperform,' reflecting expectations for relative performance.
• Price targets offer estimates of future stock value, with changes indicating evolving expectations.

Analysts consider various factors, including Regeneron's pipeline, potential catalysts, and financial health. The company's strong financials, such as a current ratio of 4.73 and more cash than debt, support a positive outlook despite challenges.

For additional information, you might find this resource helpful: Regeneron Pharmaceuticals, Inc. (REGN): History, Ownership, Mission, How It Works & Makes Money